CN113906013A - 吡啶氮氧化合物及其制备方法和用途 - Google Patents

吡啶氮氧化合物及其制备方法和用途 Download PDF

Info

Publication number
CN113906013A
CN113906013A CN202080037787.2A CN202080037787A CN113906013A CN 113906013 A CN113906013 A CN 113906013A CN 202080037787 A CN202080037787 A CN 202080037787A CN 113906013 A CN113906013 A CN 113906013A
Authority
CN
China
Prior art keywords
alkyl
radical
cycloalkyl
membered heterocycloalkyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080037787.2A
Other languages
English (en)
Other versions
CN113906013B (zh
Inventor
张琼
王中利
戴明
程凤凯
罗九
叶艳
彭建彪
郭海兵
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Jiyu Pharmaceutical Technology Co ltd
Jiangxi Jemincare Group Co Ltd
Original Assignee
Shanghai Jiyu Pharmaceutical Technology Co ltd
Jiangxi Jemincare Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Jiyu Pharmaceutical Technology Co ltd, Jiangxi Jemincare Group Co Ltd filed Critical Shanghai Jiyu Pharmaceutical Technology Co ltd
Publication of CN113906013A publication Critical patent/CN113906013A/zh
Application granted granted Critical
Publication of CN113906013B publication Critical patent/CN113906013B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22—Nitrogen and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

本发明属于药物化学领域。本发明公开了吡啶氮氧化合物及其制备方法和用途，具体地，本发明涉及一系列具有新型结构的钠离子通道的阻滞剂，及其制备方法和用途。其结构如下列通式(I)所示。这些化合物或其立体异构体、外消旋物、几何异构体、互变异构体、前药、水合物、溶剂化物或其药学上可接受的盐及药物组合物，可用于治疗或/和预防由钠离子通道(NaV)介导的相关疾病。

Description

PCT国内申请，说明书已公开。

Claims (20)

  1. PCT国内申请，权利要求书已公开。
CN202080037787.2A 2019-09-12 2020-09-11 吡啶氮氧化合物及其制备方法和用途 Active CN113906013B (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN201910863718 2019-09-12
CN2019108637186 2019-09-12
CN201911094782 2019-11-11
CN2019110947829 2019-11-11
CN2020105313811 2020-06-11
CN202010531381 2020-06-11
CN2020109233110 2020-09-04
CN202010923311 2020-09-04
PCT/CN2020/114700 WO2021047622A1 (zh) 2019-09-12 2020-09-11 吡啶氮氧化合物及其制备方法和用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410255352.5A Division CN118146148A (zh) 2019-09-12 2020-09-11 吡啶氮氧化合物及其制备方法和用途

Publications (2)

Publication Number Publication Date
CN113906013A true CN113906013A (zh) 2022-01-07
CN113906013B CN113906013B (zh) 2024-03-12

Family

ID=74866555

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080037787.2A Active CN113906013B (zh) 2019-09-12 2020-09-11 吡啶氮氧化合物及其制备方法和用途
CN202010957957.0A Active CN112479996B (zh) 2019-09-12 2020-09-11 吡啶氮氧化合物及其制备方法和用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202010957957.0A Active CN112479996B (zh) 2019-09-12 2020-09-11 吡啶氮氧化合物及其制备方法和用途

Country Status (15)

Country Link
US (1) US20230303495A9 (zh)
EP (1) EP4043437A4 (zh)
JP (1) JP2022548104A (zh)
KR (1) KR20220101606A (zh)
CN (2) CN113906013B (zh)
AU (1) AU2020346951A1 (zh)
BR (1) BR112022004495A8 (zh)
CA (1) CA3150400A1 (zh)
CL (1) CL2022000619A1 (zh)
CO (1) CO2022004594A2 (zh)
MX (1) MX2022003032A (zh)
PE (1) PE20221515A1 (zh)
TW (1) TWI770607B (zh)
WO (1) WO2021047622A1 (zh)
ZA (1) ZA202204100B (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023232117A1 (zh) * 2022-06-02 2023-12-07 上海济煜医药科技有限公司 吡啶氮氧化合物的制备方法

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4306511A1 (en) * 2021-03-11 2024-01-17 Shanghai Jemincare Pharmaceuticals Co., Ltd. Crystal form of pyridine nitrogen oxide compound and use thereof
AU2022285758A1 (en) 2021-06-04 2023-11-30 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran analogs as modulators of sodium channels
CN117813302A (zh) 2021-06-04 2024-04-02 沃泰克斯药物股份有限公司 经取代的四氢呋喃-2-甲酰胺作为钠通道调节剂
EP4347031A1 (en) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
EP4347584A1 (en) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
JP2024520643A (ja) 2021-06-04 2024-05-24 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルの調節因子としてのヒドロキシ及び（ハロ）アルコキシ置換テトラヒドロフラン
WO2022256708A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Solid dosage forms and dosing regimens comprising (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide
TW202340177A (zh) 2021-12-30 2023-10-16 美商拜歐米富士恩股份有限公司 作為 flt3抑制劑之吡嗪化合物
WO2023186102A1 (zh) * 2022-04-02 2023-10-05 武汉人福创新药物研发中心有限公司 Nav1.8抑制剂及其用途
WO2023205468A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
US20230382910A1 (en) 2022-04-22 2023-11-30 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
US20230373925A1 (en) 2022-04-22 2023-11-23 Vertex Pharma Heteroaryl compounds for the treatment of pain
WO2023205465A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2023246867A1 (zh) * 2022-06-22 2023-12-28 武汉人福创新药物研发中心有限公司 Nav1.8抑制剂

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008075465A1 (ja) * 2006-12-19 2008-06-26 Mitsui Chemicals, Inc. 植物種子用又は収穫物用殺虫組成物およびその使用方法
CN101466665A (zh) * 2006-04-11 2009-06-24 沃泰克斯药物股份有限公司 适用作电压-门控钠通道抑制剂的组合物
CN101855210A (zh) * 2007-10-11 2010-10-06 沃泰克斯药物股份有限公司 用作电压-门控钠通道抑制剂的酰胺类
CN101883758A (zh) * 2007-10-11 2010-11-10 沃泰克斯药物股份有限公司 用作电压门控的钠通道抑制剂的芳基酰胺类化合物
CN105026373A (zh) * 2013-01-31 2015-11-04 沃泰克斯药物股份有限公司 作为钠通道调节剂的吡啶酮酰胺
CN105073738A (zh) * 2013-01-31 2015-11-18 沃泰克斯药物股份有限公司 作为钠通道调节剂的喹啉及喹唑啉酰胺类
CN105814067A (zh) * 2013-12-13 2016-07-27 沃泰克斯药物股份有限公司 作为钠通道调节剂的吡啶酮酰胺的前药
WO2019014352A1 (en) * 2017-07-11 2019-01-17 Vertex Pharmaceuticals Incorporated CARBOXAMIDES AS INHIBITORS OF SODIUM CHANNELS
WO2020014246A1 (en) * 2018-07-09 2020-01-16 Lieber Institute, Inc. Pyridine carboxamide compounds for inhibiting nav1.8

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834468A (en) * 1995-07-07 1998-11-10 Zeneca Limited Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists
NZ565245A (en) * 2005-06-21 2010-07-30 Mitsui Chemicals Inc Amide derivative and pesticide containing such compound
US9656959B2 (en) * 2010-12-22 2017-05-23 Purdue Pharma L.P. Substituted pyridines as sodium channel blockers
TWI659945B (zh) * 2013-01-31 2019-05-21 維泰克斯製藥公司 作爲鈉通道調節劑之醯胺

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101466665A (zh) * 2006-04-11 2009-06-24 沃泰克斯药物股份有限公司 适用作电压-门控钠通道抑制剂的组合物
WO2008075465A1 (ja) * 2006-12-19 2008-06-26 Mitsui Chemicals, Inc. 植物種子用又は収穫物用殺虫組成物およびその使用方法
CN101855210A (zh) * 2007-10-11 2010-10-06 沃泰克斯药物股份有限公司 用作电压-门控钠通道抑制剂的酰胺类
CN101883758A (zh) * 2007-10-11 2010-11-10 沃泰克斯药物股份有限公司 用作电压门控的钠通道抑制剂的芳基酰胺类化合物
CN105026373A (zh) * 2013-01-31 2015-11-04 沃泰克斯药物股份有限公司 作为钠通道调节剂的吡啶酮酰胺
CN105073738A (zh) * 2013-01-31 2015-11-18 沃泰克斯药物股份有限公司 作为钠通道调节剂的喹啉及喹唑啉酰胺类
CN105814067A (zh) * 2013-12-13 2016-07-27 沃泰克斯药物股份有限公司 作为钠通道调节剂的吡啶酮酰胺的前药
WO2019014352A1 (en) * 2017-07-11 2019-01-17 Vertex Pharmaceuticals Incorporated CARBOXAMIDES AS INHIBITORS OF SODIUM CHANNELS
WO2020014246A1 (en) * 2018-07-09 2020-01-16 Lieber Institute, Inc. Pyridine carboxamide compounds for inhibiting nav1.8

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MANOJ KUMAR, ET AL.: "Cu(II)-Mediated Ortho-C-H Amination of Arenes with Free Amines", 《J. ORG. CHEM.》 *
MINGLIANG LI, ET AL.: "Cobalt-Catalyzed Direct C-H Thiolation of Aromatic Amides with Disulfides: Application to the Synthesis of Quetiapine", 《ORG. LETT.》 *
XIN-QI HAO ET AL.: "Copper-Mediated Direct Aryloxylation of Benzamides Assisted by an N,O-Bidentate Directing Group", 《ORG. LETT.》 *
YI JIANG, ET AL.: "Brønsted Base-Switched Selective Mono- and Dithiolation of Benzamides via Copper Catalysis", 《J. ORG. CHEM.》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023232117A1 (zh) * 2022-06-02 2023-12-07 上海济煜医药科技有限公司 吡啶氮氧化合物的制备方法

Also Published As

Publication number Publication date
US20230303495A9 (en) 2023-09-28
ZA202204100B (en) 2024-04-24
WO2021047622A1 (zh) 2021-03-18
AU2020346951A1 (en) 2022-04-28
EP4043437A1 (en) 2022-08-17
BR112022004495A2 (pt) 2022-05-31
MX2022003032A (es) 2022-07-12
CA3150400A1 (en) 2021-03-18
CL2022000619A1 (es) 2022-10-28
CN112479996B (zh) 2023-05-26
US20230026907A1 (en) 2023-01-26
CN113906013B (zh) 2024-03-12
JP2022548104A (ja) 2022-11-16
PE20221515A1 (es) 2022-10-04
KR20220101606A (ko) 2022-07-19
TWI770607B (zh) 2022-07-11
EP4043437A4 (en) 2023-10-04
CN112479996A (zh) 2021-03-12
TW202114990A (zh) 2021-04-16
CO2022004594A2 (es) 2022-07-08
BR112022004495A8 (pt) 2023-04-18

Similar Documents

Publication Publication Date Title
CN112479996B (zh) 吡啶氮氧化合物及其制备方法和用途
CN112225695B (zh) 一种氮氧化合物及其制备方法和用途
CN112457294B (zh) 一种作为NaV1.8阻滞剂的化合物及其制备方法和用途
CN111808019B (zh) 一种并环化合物及其应用
EP3766882B1 (en) Phthalazine isoxazole alkoxy derivatives, preparation method thereof, pharmaceutical composition and use thereof
JP7032378B2 (ja) スピロ－ラクタムｎｍｄａ受容体修飾因子及びその使用
JP2016537369A (ja) カゼインキナーゼ１ｄ／ｅ阻害剤としての置換された４，５，６，７−テトラヒドロピラゾロ［１，５−ａ］ピラジン誘導体
BR112019014688A2 (pt) Derivados de carbamato de 1,1,1-trifluoro-3-hidroxipropan-2-il como inibidores de magl
TW202309020A (zh) KEAP1-Nrf2蛋白-蛋白交互作用抑制劑
EP4339189A1 (en) Nmda receptor antagonist and use thereof
EP3388433B1 (en) Phthalazine derivatives, and preparation method, pharmaceutical composition and use thereof
EP3724194B1 (en) Substituted azetidine dihydrothienopyrimidines and their use as phosphodiesterase inhibitors
JPWO2021047622A5 (zh)
KR20220106778A (ko) 간 x 수용체 작용제로서의 1,2,4-옥사디아졸 유도체
EP2968207A1 (en) Histone deacetylase inhibitors and compositions
EP3950693A1 (en) Thienoheterocyclic derivative, preparation method therefor and medical use thereof
EP3283487B1 (en) Pyridopyrimidinones and their use as nmda receptor modulators
CN113272315B (zh) 一类类固醇化合物及其用途
WO2023023670A1 (en) Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease
CN107344936B (zh) 三唑哒嗪类衍生物、其制备方法、药物组合物和用途
CN118146148A (zh) 吡啶氮氧化合物及其制备方法和用途
WO2019115775A1 (en) Substituted tetrahydropyran dihydrothienopyrimidines and their use as phosphodiesterase inhibitors
US11780843B2 (en) Compounds active towards nuclear receptors
WO2023023671A1 (en) Compositions and methods for treatment of neurodegenerative and mitochondrial disease
WO2022268154A1 (zh) 新型抗乙肝化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40061625

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant